Ishino Y , Shinagawa H , Makino K , Amemura M , Nakata A . Nucleotide sequence of the iap gene, responsible for alkaline phosphatase isozyme conversion in Escherichia coli, and identification of the gene product . J Bacteriol . 1987 ; 169 ( 12 ): 5429 – 33 .

Bhaya D , Davison M , Barrangou R . CRISPR-Cas systems in bacteria and archaea: versatile small RNAs for adaptive defense and regulation . Annu Rev Genet . 2011 ; 45 ( 1 ): 273 – 97 .

Brouns SJ , Jore MM , Lundgren M , Westra ER , Slijkhuis RJ , Snijders AP , et al . Small CRISPR RNAs guide antiviral defense in prokaryotes . Science . 2008 ; 321 ( 5891 ): 960 – 4 .

Makarova KS , Wolf YI , Alkhnbashi OS , Costa F , Shah SA , Saunders SJ , et al . An updated evolutionary classification of CRISPR-Cas systems . Nat Rev Microbiol . 2015 ; 13 ( 11 ): 722 – 36 .

Rasul MF , Hussen BM , Salihi A , Ismael BS , Jalal PJ , Zanichelli A , et al . Strategies to overcome the main challenges of the use of CRISPR/Cas9 as a replacement for cancer therapy . Mol Cancer . 2022 ; 21 ( 1 ): 64 .

Jinek M , Chylinski K , Fonfara I , Hauer M , Doudna JA , Charpentier E . A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity . Science . 2012 ; 337 ( 6096 ): 816 – 21 .

Mojica FJM , Díez-Villaseñor C , García-Martínez J , Almendros C . Short motif sequences determine the targets of the prokaryotic CRISPR defence system . Microbiology . 2009 ; 155 ( Pt 3 ): 733 – 40 .

Iacomino G . miRNAs: the road from bench to bedside . Genes . 2023 ; 14 ( 2 ): 314 .

Martinez-Lage M , Puig-Serra P , Menendez P , Torres-Ruiz R , Rodriguez-Perales S . CRISPR/Cas9 for cancer therapy: hopes and challenges . Biomedicines . 2018 ; 6 ( 4 ): 105 .

Miyoshi J , Zhu Z , Luo A , Toden S , Zhou X , Izumi D , et al . A microRNA based liquid biopsy signature for the early detection of esophageal squamous cell carcinoma: a retrospective, prospective and multicenter study . Mol Cancer . 2022 ; 21 ( 1 ): 44 .

Krol J , Loedige I , Filipowicz W . The widespread regulation of microRNA biogenesis, function and decay . Nat Rev Genet . 2010 ; 11 ( 9 ): 597 – 610 .

Peng Y , Croce CM . The role of microRNAs in human cancer . Signal Transduct Target Ther . 2016 ; 1 : 15004 .

Hussen BM , Hidayat HJ , Salihi A , Sabir DK , Taheri M , Ghafouri-Fard S . MicroRNA: a signature for cancer progression . Biomed Pharmacother . 2021 ; 138 : 111528 .

Liang L , Cen H , Huang J , Qin A , Xu W , Wang S , et al . The reversion of DNA methylation-induced miRNA silence via biomimetic nanoparticles-mediated gene delivery for efficient lung adenocarcinoma therapy . Mol Cancer . 2022 ; 21 ( 1 ): 186 .

Shen P , Yang T , Chen Q , Yuan H , Wu P , Cai B , et al . CircNEIL3 regulatory loop promotes pancreatic ductal adenocarcinoma progression via miRNA sponging and A-to-I RNA-editing . Mol Cancer . 2021 ; 20 ( 1 ): 51 .

Nombela P , Miguel-López B , Blanco S . The role of m6A, m5C and Ψ RNA modifications in cancer: novel therapeutic opportunities . Mol Cancer . 2021 ; 20 ( 1 ): 18 .

Taghavipour M , Sadoughi F , Mirzaei H , Yousefi B , Moazzami B , Chaichian S , et al . Apoptotic functions of microRNAs in pathogenesis, diagnosis, and treatment of endometriosis . Cell Biosci . 2020 ; 10 ( 1 ): 12 .

Kang M , Tang B , Li J , Zhou Z , Liu K , Wang R , et al . Identification of miPEP133 as a novel tumor-suppressor microprotein encoded by miR-34a pri-miRNA . Mol Cancer . 2020 ; 19 ( 1 ): 143 .

Leichter AL , Sullivan MJ , Eccles MR , Chatterjee A . MicroRNA expression patterns and signalling pathways in the development and progression of childhood solid tumours . Mol Cancer . 2017 ; 16 ( 1 ): 15 .

Chan SH , Wang LH . Regulation of cancer metastasis by microRNAs . J Biomed Sci . 2015 ; 22 ( 1 ): 9 .

Bhat AA , Younes SN , Raza SS , Zarif L , Nisar S , Ahmed I , et al . Role of noncoding RNA networks in leukemia progression, metastasis and drug resistance . Mol Cancer . 2020 ; 19 ( 1 ): 57 .

Wang Y , Wang L , Chen C , Chu X . New insights into the regulatory role of microRNA in tumor angiogenesis and clinical implications . Mol Cancer . 2018 ; 17 ( 1 ): 22 .

Dexheimer PJ , Cochella L . MicroRNAs: from mechanism to organism . Front Cell Dev Biol . 2020 ; 8 : 409 .

De Rie D , Abugessaisa I , Alam T , Arner E , Arner P , Ashoor H , et al . An integrated expression atlas of miRNAs and their promoters in human and mouse . Nat Biotechnol . 2017 ; 35 ( 9 ): 872 – 8 .

Kim YK , Kim VN . Processing of intronic microRNAs . Embo J . 2007 ; 26 ( 3 ): 775 – 83 .

Dastmalchi N , Safaralizadeh R , Banan Khojasteh SM , Sam MR , Latifi-Navid S , Hussen BM , et al . An updated review of the cross-talk between microRNAs and epigenetic factors in cancers . Curr Med Chem . 2021 ; 28 ( 42 ): 8722 – 32 .

Tanzer A , Stadler PF . Molecular evolution of a microRNA cluster . J Mol Biol . 2004 ; 339 ( 2 ): 327 – 35 .

Bohnsack MT , Czaplinski K , Gorlich D . Exportin 5 is a RanGTP-dependent dsRNA-binding protein that mediates nuclear export of pre-miRNAs . RNA . 2004 ; 10 ( 2 ): 185 – 91 .

Carthew RW , Sontheimer EJ . Origins and mechanisms of miRNAs and siRNAs . Cell . 2009 ; 136 ( 4 ): 642 – 55 .

Eulalio A , Huntzinger E , Nishihara T , Rehwinkel J , Fauser M , Izaurralde E . Deadenylation is a widespread effect of miRNA regulation . RNA . 2009 ; 15 ( 1 ): 21 – 32 .

Wilczynska A , Bushell M . The complexity of miRNA-mediated repression . Cell Death Differ . 2015 ; 22 ( 1 ): 22 – 33 .

Xu W , San Lucas A , Wang Z , Liu Y . Identifying microRNA targets in different gene regions . BMC Bioinf . 2014 ; 15 : S4 .

Valinezhad Orang A , Safaralizadeh R , Kazemzadeh-Bavili M . Mechanisms of miRNA-mediated gene regulation from common downregulation to mRNA-specific upregulation . Int J Genomics . 2014 ; 2014 : 970607 .

Zhang Y , Fan M , Zhang X , Huang F , Wu K , Zhang J , et al . Cellular micro-RNAs up-regulate transcription via interaction with promoter TATA-box motifs . RNA . 2014 ; 20 ( 12 ): 1878 – 89 .

Monroig-Bosque PDC , Shah MY , Fu X , Fuentes-Mattei E , Ling H , Ivan C , et al . OncomiR-10b hijacks the small molecule inhibitor linifanib in human cancers . Sci Rep . 2018 ; 8 ( 1 ): 13106 .

Fu Z , Wang L , Li S , Chen F , Au-Yeung KK-W , Shi C . MicroRNA as an important target for anticancer drug development . Front Pharmacol . 2021 ; 12 : 736323 .

Vasudevan S , Tong Y , Steitz JA . Switching from repression to activation: microRNAs can up-regulate translation . Science . 2007 ; 318 ( 5858 ): 1931 – 4 .

Friedman RC , Farh KK , Burge CB , Bartel DP . Most mammalian mRNAs are conserved targets of microRNAs . Genome Res . 2009 ; 19 ( 1 ): 92 – 105 .

Iacomino G , Siani A . Role of microRNAs in obesity and obesity-related diseases . Genes Nutr . 2017 ; 12 : 23 .

Lui PY , Jin DY , Stevenson NJ . MicroRNA: master controllers of intracellular signaling pathways . Cell Mol Life Sci . 2015 ; 72 ( 18 ): 3531 – 42 .

Gambari R , Brognara E , Spandidos DA , Fabbri E . Targeting oncomiRNAs and mimicking tumor suppressor miRNAs: new trends in the development of miRNA therapeutic strategies in oncology (Review) . Int J Oncol . 2016 ; 49 ( 1 ): 5 – 32 .

Rhim J , Baek W , Seo Y , Kim JH . From molecular mechanisms to therapeutics: understanding microRNA-21 in cancer . Cells . 2022 ; 11 : 18 .

Misso G , Di Martino MT , De Rosa G , Farooqi AA , Lombardi A , Campani V , et al . Mir-34: a new weapon against cancer? . Mol Ther Nucleic Acids . 2014 ; 3 ( 9 ): e195 .

Fuziwara CS , Kimura ET . Insights into regulation of the miR-17-92 cluster of miRNAs in cancer . Front Med . 2015 ; 2 : 64 .

Park SM , Gaur AB , Lengyel E , Peter ME . The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2 . Genes Dev . 2008 ; 22 ( 7 ): 894 – 907 .

Hussen BM , Salihi A , Abdullah ST , Rasul MF , Hidayat HJ , Hajiesmaeili M , et al . Signaling pathways modulated by miRNAs in breast cancer angiogenesis and new therapeutics . Pathol Res Pract . 2022 ; 230 : 153764 .

Ye J , Guo R , Shi Y , Qi F , Guo C , Yang L . miR-155 regulated inflammation response by the SOCS1-STAT3-PDCD4 axis in atherogenesis . Mediators Inflamm . 2016 ; 2016 : 8060182 .

Alexandrov P , Zhai Y , Li W , Lukiw W . Lipopolysaccharide-stimulated, NF-κB-, miRNA-146a- and miRNA-155-mediated molecular-genetic communication between the human gastrointestinal tract microbiome and the brain . Folia Neuropathol . 2019 ; 57 ( 3 ): 211 – 9 .

Kalsotra A , Wang K , Li PF , Cooper TA . MicroRNAs coordinate an alternative splicing network during mouse postnatal heart development . Genes Dev . 2010 ; 24 ( 7 ): 653 – 8 .

Suzuki H , Maruyama R , Yamamoto E , Kai M . Epigenetic alteration and microRNA dysregulation in cancer . Front Genet . 2013 ; 4 : 258 .

Dittmar RL , Sen S . Chapter 4 - microRNAs in exosomes in cancer . In: Chakrabarti DJ , Mitra DS , editors. Cancer and noncoding RNAs . Boston : Academic Press ; 2018 . p. 59 – 78 .

Menon A , Abd-Aziz N , Khalid K , Poh CL , Naidu R . miRNA: a promising therapeutic target in cancer . Int J Mol Sci . 2022 ; 23 ( 19 ): 11502 .

Katti A , Diaz BJ , Caragine CM , Sanjana NE , Dow LE . CRISPR in cancer biology and therapy . Nat Rev Cancer . 2022 ; 22 ( 5 ): 259 – 79 .

Nguyen DD , Chang S . Development of novel therapeutic agents by inhibition of oncogenic microRNAs . Int J Mol Sci . 2017 ; 19 ( 1 ): 65 .

He L , He X , Lim LP , De Stanchina E , Xuan Z , Liang Y , et al . A micro-RNA component of the p53 tumour suppressor network . Nature . 2007 ; 447 ( 7148 ): 1130 – 4 .

Wen D , Danquah M , Chaudhary AK , Mahato RI . Small molecules targeting microRNA for cancer therapy: promises and obstacles . J Control Release . 2015 ; 219 : 237 - 47 .

Trang P , Medina PP , Wiggins JF , Ruffino L , Kelnar K , Omotola M , et al . Regression of murine lung tumors by the let-7 microRNA . Oncogene . 2010 ; 29 ( 11 ): 1580 – 7 .

Daige CL , Wiggins JF , Priddy L , Nelligan-Davis T , Zhao J , Brown D . Systemic delivery of a miR34a mimic as a potential therapeutic for liver cancer . Mol Cancer Ther . 2014 ; 13 ( 10 ): 2352 – 60 .

Bader AG , Brown D , Winkler M . The promise of microRNA replacement therapy . Cancer Res . 2010 ; 70 ( 18 ): 7027 – 30 .

Zhang S , Cheng Z , Wang Y , Han T . The risks of miRNA therapeutics: in a drug target perspective . Drug Des Devel Ther . 2021 ; 15 : 721 - 33 .

Jin HY , Gonzalez-Martin A , Miletic AV , Lai M , Knight S , Sabouri-Ghomi M , et al . Transfection of microRNA mimics should be used with caution . Front Genet . 2015 ; 6 : 340 .

Søkilde R , Newie I , Persson H , Borg Å , Rovira C . Passenger strand loading in overexpression experiments using microRNA mimics . RNA Biol . 2015 ; 12 ( 8 ): 787 – 91 .

Ma L , Reinhardt F , Pan E , Soutschek J , Bhat B , Marcusson EG , et al . Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model . Nat Biotechnol . 2010 ; 28 ( 4 ): 341 – 7 .

Gong H , Chen H , Xiao P , Huang N , Han X , Zhang J , et al . miR-146a impedes the anti-aging effect of AMPK via NAMPT suppression and NAD + /SIRT inactivation . Signal Transduct Target Ther . 2022 ; 7 ( 1 ): 66 .

Xu H , Guo S , Li W , Yu P . The circular RNA Cdr1as, via miR-7 and its targets, regulates insulin transcription and secretion in islet cells . Sci Rep . 2015 ; 5 : 12453 .

Su Y , Hou W , Zhang C , Ji P , Hu R , Zhang Q , et al . Long non-coding RNA ZFAS1 regulates cell proliferation and invasion in cervical cancer via the miR-190a-3p/KLF6 axis . Bioengineered . 2022 ; 13 ( 2 ): 3840 – 51 .

Ebert MS , Sharp PA . MicroRNA sponges: progress and possibilities . RNA . 2010 ; 16 ( 11 ): 2043 – 50 .

Ahmadi S , Sharifi M , Salehi R . Locked nucleic acid inhibits miR-92a-3p in human colorectal cancer, induces apoptosis and inhibits cell proliferation . Cancer Gene Ther . 2016 ; 23 ( 7 ): 199 – 205 .

De Cola A , Lamolinara A , Lanuti P , Rossi C , Iezzi M , Marchisio M , et al . MiR-205-5p inhibition by locked nucleic acids impairs metastatic potential of breast cancer cells . Cell Death Dis . 2018 ; 9 ( 8 ): 821 .

Ishida M , Selaru FM . miRNA-based therapeutic strategies . Curr Anesthesiol Rep . 2013 ; 1 ( 1 ): 63 – 70 .

Owczarzy R , You Y , Groth CL , Tataurov AV . Stability and mismatch discrimination of locked nucleic acid-DNA duplexes . Biochemistry . 2011 ; 50 ( 43 ): 9352 – 67 .

Bader AG , Brown D , Stoudemire J , Lammers P . Developing therapeutic microRNAs for cancer . Gene Ther . 2011 ; 18 ( 12 ): 1121 – 6 .

Singh S , Narang AS , Mahato RI . Subcellular fate and off-target effects of siRNA, shRNA, and miRNA . Pharm Res . 2011 ; 28 ( 12 ): 2996 – 3015 .

Takagi S , Nakajima M , Kida K , Yamaura Y , Fukami T , Yokoi T . MicroRNAs regulate human hepatocyte nuclear factor 4α, modulating the expression of metabolic enzymes and cell cycle . J Biol Chem . 2010 ; 285 ( 7 ): 4415 – 22 .

Hong DS , Kang YK , Borad M , Sachdev J , Ejadi S , Lim HY , et al . Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours . Br J Cancer . 2020 ; 122 ( 11 ): 1630 – 7 .

Fortunato O , Iorio MV . The therapeutic potential of microRNAs in cancer: illusion or opportunity? . Pharmaceuticals . 2020 ; 13 ( 12 ): 438 .

Chang H , Yi B , Ma R , Zhang X , Zhao H , Xi Y . CRISPR/cas9, a novel genomic tool to knock down microRNA in vitro and in vivo . Sci Rep . 2016 ; 6 : 22312 .

Huo W , Zhao G , Yin J , Ouyang X , Wang Y , Yang C , et al . Lentiviral CRISPR/Cas9 vector mediated miR-21 gene editing inhibits the epithelial to mesenchymal transition in ovarian cancer cells . J Cancer . 2017 ; 8 ( 1 ): 57 – 64 .

El Fatimy R , Subramanian S , Uhlmann EJ , Krichevsky AM . Genome editing reveals glioblastoma addiction to microRNA-10b . Mol Ther . 2017 ; 25 ( 2 ): 368 – 78 .

Cyranoski D . CRISPR gene-editing tested in a person for the first time . Nature . 2016 ; 539 ( 7630 ): 479 .

Price C , Chen J . MicroRNAs in cancer biology and therapy: current status and perspectives . Genes Dis . 2014 ; 1 ( 1 ): 53 – 63 .

Jing W , Zhang X , Sun W , Hou X , Yao Z , Zhu Y . CRISPR/CAS9-mediated genome editing of miRNA-155 inhibits proinflammatory cytokine production by RAW264.7 cells . Biomed Res Int . 2015 ; 2015 : 326042 .

Bala S , Marcos M , Kodys K , Csak T , Catalano D , Mandrekar P , et al . Upregulation of microRNA-155 in macrophages contributes to increased tumor necrosis factor α (TNFα) production via increased mRNA half-life in alcoholic liver disease . J Biol Chem . 2011 ; 286 ( 2 ): 1436 – 44 .

Li Z , Zhou X , Wei M , Gao X , Zhao L , Shi R , et al . In vitro and in vivo RNA inhibition by CD9-HuR functionalized exosomes encapsulated with miRNA or CRISPR/dCas9 . Nano Lett . 2018 ; 19 ( 1 ): 19 – 28 .

Narayanan A , Hill-Teran G , Moro A , Ristori E , Kasper DM , Roden AC , et al . In vivo mutagenesis of miRNA gene families using a scalable multiplexed CRISPR/Cas9 nuclease system . Sci Rep . 2016 ; 6 : 32386 .

Zhang YH , Wu LZ , Liang HL , Yang Y , Qiu J , Kan Q , et al . Pulmonary surfactant synthesis in miRNA-26a-1/miRNA-26a-2 double knockout mice generated using the CRISPR/Cas9 system . Am J Transl Res . 2017 ; 9 ( 2 ): 355 – 6 .

Godden AM , Antonaci M , Ward NJ , Van Der Lee M , Abu-Daya A , Guille M , et al . An efficient miRNA knockout approach using CRISPR-Cas9 in Xenopus . Dev Biol . 2022 ; 483 : 66 - 75 .

Senís E , Mockenhaupt S , Rupp D , Bauer T , Paramasivam N , Knapp B , et al . TALEN/CRISPR-mediated engineering of a promoterless anti-viral RNAi hairpin into an endogenous miRNA locus . Nucl Acids Res . 2017 ; 45 ( 1 ): e3 .

Wang Z , Sun X , Zhang X , Dong B , Yu H . Development of a miRNA sensor by an inducible CRISPR-Cas9 construct in Ciona embryogenesis . Mol Biotechnol . 2021 ; 63 ( 7 ): 613 – 20 .

Zhang Z , Ursin R , Mahapatra S , Gallicano GI . CRISPR/CAS9 ablation of individual miRNAs from a miRNA family reveals their individual efficacies for regulating cardiac differentiation . Mech Dev . 2018 ; 150 : 10 - 20 .

Michaels YS , Wu Q , Fulga TA . Interrogation of functional miRNA–target interactions by CRISPR/Cas9 genome engineering . In: Dalmay T , editor. MicroRNA detection and target identification . Humana, New York, NY : Springer ; 2017 .p. 79 – 97 .

Matano M , Date S , Shimokawa M , Takano A , Fujii M , Ohta Y , et al . Modeling colorectal cancer using CRISPR-Cas9–mediated engineering of human intestinal organoids . Nat Med . 2015 ; 21 ( 3 ): 256 – 62 .

Zhao Y , Shi C , Zhao Y , Xin Z , Liu P , Zhang C , et al . Construction of miRNA-29b1 knockout mice based on CRISPR/Cas9 technology . Chin J Comp Med . 2016 ; 26 ( 12 ): 1 – 4 .

Kurata JS , Lin RJ . MicroRNA-focused CRISPR-Cas9 library screen reveals fitness-associated miRNAs . RNA . 2018 ; 24 ( 7 ): 966 – 81 .

Lataniotis L , Albrecht A , Kok FO , Monfries CA , Benedetti L , Lawson ND , et al . CRISPR/Cas9 editing reveals novel mechanisms of clustered microRNA regulation and function . Sci Rep . 2017 ; 7 ( 1 ): 8585 .

Voytas DF . Plant genome engineering with sequence-specific nucleases . Annu Rev Plant Biol . 2013 ; 64 : 327 - 50 .

Zhang JP , Li XL , Li GH , Chen W , Arakaki C , Botimer GD , et al . Efficient precise knockin with a double cut HDR donor after CRISPR/Cas9-mediated double-stranded DNA cleavage . Genome Biol . 2017 ; 18 ( 1 ): 35 .

Sander JD , Dahlborg EJ , Goodwin MJ , Cade L , Zhang F , Cifuentes D , et al . Selection-free zinc-finger-nuclease engineering by context-dependent assembly (CoDA) . Nat Methods . 2011 ; 8 ( 1 ): 67 – 9 .

Cermak T , Doyle EL , Christian M , Wang L , Zhang Y , Schmidt C , et al . Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting . Nucleic Acids Res . 2011 ; 39 ( 12 ): e82 .

Bin Moon S , Lee JM , Kang JG , Lee N-E , Ha D-I , Kim DY , et al . Highly efficient genome editing by CRISPR-Cpf1 using CRISPR RNA with a uridinylate-rich 3′-overhang . Nat Commun . 2018 ; 9 ( 1 ): 3651 .

Wang JY , Pausch P , Doudna JA . Structural biology of CRISPR–Cas immunity and genome editing enzymes . Nat Rev Microbiol . 2022 ; 20 ( 11 ): 641 – 56 .

Zhang H , Qin C , An C , Zheng X , Wen S , Chen W , et al . Application of the CRISPR/Cas9-based gene editing technique in basic research, diagnosis, and therapy of cancer . Mol Cancer . 2021 ; 20 ( 1 ): 126 .

Peng S , Tan Z , Chen S , Lei C , Nie Z . Integrating CRISPR-Cas12a with a DNA circuit as a generic sensing platform for amplified detection of microRNA . Chem Sci . 2020 ; 11 ( 28 ): 7362 – 8 .

Anzalone AV , Koblan LW , Liu DR . Genome editing with CRISPR-Cas nucleases, base editors, transposases and prime editors . Nat Biotechnol . 2020 ; 38 ( 7 ): 824 – 44 .

Gleditzsch D , Pausch P , Müller-Esparza H , Özcan A , Guo X , Bange G , et al . PAM identification by CRISPR-Cas effector complexes: diversified mechanisms and structures . RNA Biol . 2019 ; 16 ( 4 ): 504 – 17 .

Makarova KS , Wolf YI , Iranzo J , Shmakov SA , Alkhnbashi OS , Brouns SJJ , et al . Evolutionary classification of CRISPR-Cas systems: a burst of class 2 and derived variants . Nat Rev Microbiol . 2020 ; 18 ( 2 ): 67 – 83 .

Pelea O , Fulga TA , Sauka-Spengler T . RNA-responsive gRNAs for controlling CRISPR activity: current advances, future directions, and potential applications . CRISPR J . 2022 ; 5 ( 5 ): 642 – 59 .

Nishimasu H , Ran FA , Hsu PD , Konermann S , Shehata SI , Dohmae N , et al . Crystal structure of Cas9 in complex with guide RNA and target DNA . Cell . 2014 ; 156 ( 5 ): 935 – 49 .

Zhao Z , Li C , Tong F , Deng J , Huang G , Sang Y . Review of applications of CRISPR-Cas9 gene-editing technology in cancer research . Biol Proced Online . 2021 ; 23 ( 1 ): 14 .

Jiang F , Zhou K , Ma L , Gressel S , Doudna JA . Structural biology. A Cas9-guide RNA complex preorganized for target DNA recognition . Science . 2015 ; 348 ( 6242 ): 1477 – 81 .

Anders C , Niewoehner O , Duerst A , Jinek M . Structural basis of PAM-dependent target DNA recognition by the Cas9 endonuclease . Nature . 2014 ; 513 ( 7519 ): 569 – 73 .

Pacesa M , Loeff L , Querques I , Muckenfuss LM , Sawicka M , Jinek M . R-loop formation and conformational activation mechanisms of Cas9 . Nature . 2022 ; 609 ( 7925 ): 191 – 6 .

Globyte V , Lee SH , Bae T , Kim JS , Joo C . CRISPR/Cas9 searches for a protospacer adjacent motif by lateral diffusion . Embo J . 2019 ; 38 ( 4 ): e99466 .

Cofsky JC , Soczek KM , Knott GJ , Nogales E , Doudna JA . CRISPR-Cas9 bends and twists DNA to read its sequence . Nat Struct Mol Biol . 2022 ; 29 ( 4 ): 395 – 402 .

Jiang F , Taylor DW , Chen JS , Kornfeld JE , Zhou K , Thompson AJ , et al . Structures of a CRISPR-Cas9 R-loop complex primed for DNA cleavage . Science . 2016 ; 351 ( 6275 ): 867 – 71 .

Ivanov IE , Wright AV , Cofsky JC , Aris KDP , Doudna JA , Bryant Z . Cas9 interrogates DNA in discrete steps modulated by mismatches and supercoiling . Proc Natl Acad Sci U S A . 2020 ; 117 ( 11 ): 5853 – 60 .

Cammaerts S , Strazisar M , De Rijk P , Del Favero J . Genetic variants in microRNA genes: impact on microRNA expression, function, and disease . Front Genet . 2015 ; 6 : 186 .

Zhou J , Deng K , Cheng Y , Zhong Z , Tian L , Tang X , et al . CRISPR-Cas9 based genome editing reveals new insights into microRNA function and regulation in rice . Front Plant Sci . 2017 ; 8 : 1598 .

Zhao Y , Dai Z , Liang Y , Yin M , Ma K , He M , et al . Sequence-specific inhibition of microRNA via CRISPR/CRISPRi system . Sci Rep . 2014 ; 4 : 3943 .

Sheng P , Fields C , Aadland K , Wei T , Kolaczkowski O , Gu T , et al . Dicer cleaves 5'-extended microRNA precursors originating from RNA polymerase II transcription start sites . Nucleic Acids Res . 2018 ; 46 ( 11 ): 5737 – 52 .

Abdollah NA , Theva Das K , Narazah M , Abdul Razak SR . Sequence-specific inhibition of microRNA-130a gene by CRISPR/Cas9 system in breast cancer cell line . J Phys Conf Ser . 2017 ; 851 : 012037 . https://doi.org/10.1088/1742-6596/851/1/012037 https://doi.org/10.1088/1742-6596/851/1/012037 .

Park HH , Triboulet R , Bentler M , Guda S , Du P , Xu H , et al . DROSHA knockout leads to enhancement of viral titers for vectors encoding miRNA-adapted shRNAs . Mol Ther Nucleic Acids . 2018 ; 12 : 591 - 9 .

Shmakov S , Smargon A , Scott D , Cox D , Pyzocha N , Yan W , et al . Diversity and evolution of class 2 CRISPR-Cas systems . Nat Rev Microbiol . 2017 ; 15 ( 3 ): 169 – 82 .

Carabias A , Fuglsang A , Temperini P , Pape T , Sofos N , Stella S , et al . Structure of the mini-RNA-guided endonuclease CRISPR-Cas12j3 . Nat Commun . 2021 ; 12 ( 1 ): 4476 .

Tsuchida CA , Zhang S , Doost MS , Zhao Y , Wang J , et al . Chimeric CRISPR-CasX enzymes and guide RNAs for improved genome editing activity . Mol Cell . 2022 ; 82 ( 6 ): 1199 – 209 .

Huang CJ , Adler BA , Doudna JA . A naturally DNase-free CRISPR-Cas12c enzyme silences gene expression . Mol Cell . 2022 ; 82 ( 11 ): 2148 – 60.e4 .

Xiao R , Li Z , Wang S , Han R , Chang L . Structural basis for substrate recognition and cleavage by the dimerization-dependent CRISPR-Cas12f nuclease . Nucleic Acids Res . 2021 ; 49 ( 7 ): 4120 – 8 .

Takeda SN , Nakagawa R , Okazaki S , Hirano H , Kobayashi K , Kusakizako T , et al . Structure of the miniature type V-F CRISPR-Cas effector enzyme . Mol Cell . 2021 ; 81 ( 3 ): 558 – 70.e3 .

Pausch P , Soczek KM , Herbst DA , Tsuchida CA , Al-Shayeb B , Banfield JF , et al . DNA interference states of the hypercompact CRISPR–CasΦ effector . Nat Struct Mol Biol . 2021 ; 28 ( 8 ): 652 – 61 .

Li Z , Zhang H , Xiao R , Han R , Chang L . Cryo-EM structure of the RNAguided ribonuclease Cas12g . Nat Chem Biol . 2021 ; 17 ( 4 ): 387 – 93 .

Dong D , Ren K , Qiu X , Zheng J , Guo M , Guan X , et al . The crystal structure of Cpf1 in complex with CRISPR RNA . Nature . 2016 ; 532 ( 7600 ): 522 – 6 .

Swarts DC , Van Der Oost J , Jinek M . Structural basis for guide RNA processing and seed-dependent DNA targeting by CRISPR-Cas12a . Mol Cell . 2017 ; 66 ( 2 ): 221 – 33.e4 .

Stella S , Alcón P , Montoya G . Structure of the Cpf1 endonuclease R-loop complex after target DNA cleavage . Nature . 2017 ; 546 ( 7659 ): 559 – 63 .

Stella S , Mesa P , Thomsen J , Paul B , Alcón P , Jensen SB , et al . Conformational activation promotes CRISPR-Cas12a catalysis and resetting of the endonuclease activity . Cell . 2018 ; 175 ( 7 ): 1856 – 71.e21 .

Zetsche B , Gootenberg JS , Abudayyeh OO , Slaymaker IM , Makarova KS , Essletzbichler P , et al . Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system . Cell . 2015 ; 163 ( 3 ): 759 – 71 .

Huang X , Sun W , Cheng Z , Chen M , Li X , Wang J , et al . Structural basis for two metal-ion catalysis of DNA cleavage by Cas12i2 . Nat Commun . 2020 ; 11 ( 1 ): 5241 .

Swarts DC , Jinek M . Mechanistic insights into the cis- and transacting DNase activities of Cas12a . Mol Cell . 2019 ; 73 ( 3 ): 589 – 600.e4 .

Jiang W , Singh J , Allen A , Li Y , Kathiresan V , Qureshi O , et al . CRISPR-Cas12a nucleases bind flexible dna duplexes without RNA/DNA complementarity . ACS Omega . 2019 ; 4 ( 17 ): 17140 – 7 .

Paul B , Chaubet L , Verver DE , Montoya G . Mechanics of CRISPR-Cas12a and engineered variants on λ-DNA . Nucleic Acids Res . 2022 ; 50 ( 9 ): 5208 – 25 .

Jiang Q , Meng X , Meng L , Chang N , Xiong J , Cao H , et al . Small indels induced by CRISPR/Cas9 in the 5' region of microRNA lead to its depletion and Drosha processing retardance . RNA Biol . 2014 ; 11 ( 10 ): 1243 – 9 .

Chen X . MicroRNA biogenesis and function in plants . FEBS Lett . 2005 ; 579 ( 26 ): 5923 – 31 .

Budak H , Akpinar BA . Plant miRNAs: biogenesis, organization and origins . Funct Integr Genomics . 2015 ; 15 ( 5 ): 523 – 31 .

Ha M , Kim VN . Regulation of microRNA biogenesis . Nat Rev Mol Cell Biol . 2014 ; 15 ( 8 ): 509 – 24 .

Lewis B , Shih IH , Jones-Rhoades M , Bartel D , Burge C . Prediction of mammalian MicroRNA Targets . Cell . 2004 ; 115 : 787 - 98 .

Bartel DP . MicroRNAs: target recognition and regulatory functions . Cell . 2009 ; 136 ( 2 ): 215 – 33 .

Chung PJ , Chung H , Oh N , Choi J , Bang SW , Jung SE , et al . Efficiency of recombinant CRISPR/rCas9-mediated miRNA gene editing in rice . Int J Mol Sci . 2020 ; 21 ( 24 ): 9606 .

Burke JM , Kelenis DP , Kincaid RP , Sullivan CS . A central role for the primary microRNA stem in guiding the position and efficiency of Drosha processing of a viral pri-miRNA . RNA . 2014 ; 20 ( 7 ): 1068 – 77 .

Friedland AE , Tzur YB , Esvelt KM , Colaiácovo MP , Church GM , Calarco JA . Heritable genome editing in C. elegans via a CRISPR-Cas9 system . Nat Methods . 2013 ; 10 ( 8 ): 741 – 3 .

Wu X , Kriz AJ , Sharp PA . Target specificity of the CRISPR-Cas9 system . Quant Biol . 2014 ; 2 ( 2 ): 59 – 70 .

Cao J , Xiao Q , Yan Q . The multiplexed CRISPR targeting platforms . Drug Discov Today Technol . 2018 ; 28 : 53 - 61 .

Ernst MPT , Broeders M , Herrero-Hernandez P , Oussoren E , Van Der Ploeg AT , Pijnappel W . Ready for repair? Gene editing enters the clinic for the treatment of human disease . Mol Ther Methods Clin Dev . 2020 ; 18 : 532 - 57 .

Cullot G , Boutin J , Toutain J , Prat F , Pennamen P , Rooryck C , et al . CRISPR-Cas9 genome editing induces megabase-scale chromosomal truncations . Nat Commun . 2019 ; 10 ( 1 ): 1136 .

Kosicki M , Tomberg K , Bradley A . Repair of double-strand breaks induced by CRISPR-Cas9 leads to large deletions and complex rearrangements . Nat Biotechnol . 2018 ; 36 ( 8 ): 765 – 71 .

Karvelis T , Bigelyte G , Young JK , Hou Z , Zedaveinyte R , Budre K , et al . PAM recognition by miniature CRISPR-Cas12f nucleases triggers programmable double-stranded DNA target cleavage . Nucleic Acids Res . 2020 ; 48 ( 9 ): 5016 – 23 .

Pausch P , Al-Shayeb B , Bisom-Rapp E , Tsuchida CA , Li Z , Cress BF , et al . CRISPR-CasΦ from huge phages is a hypercompact genome editor . Science . 2020 ; 369 ( 6501 ): 333 – 7 .

Harrington LB , Burstein D , Chen JS , Paez-Espino D , Ma E , Witte IP , et al . Programmed DNA destruction by miniature CRISPR-Cas14 enzymes . Science . 2018 ; 362 ( 6416 ): 839 – 42 .

Strohkendl I , Saifuddin FA , Rybarski JR , Finkelstein IJ , Russell R . kinetic basis for DNA target specificity of CRISPR-Cas12a . Mol Cell . 2018 ; 71 ( 5 ): 816 – 24.e3 .

Kleinstiver BP , Tsai SQ , Prew MS , Nguyen NT , Welch MM , Lopez JM , et al . Genome-wide specificities of CRISPR-Cas Cpf1 nucleases in human cells . Nat Biotechnol . 2016 ; 34 ( 8 ): 869 – 74 .

Kim D , Kim J , Hur JK , Been KW , Yoon SH , Kim JS . Genome-wide analysis reveals specificities of Cpf1 endonucleases in human cells . Nat Biotechnol . 2016 ; 34 ( 8 ): 863 – 8 .

Zetsche B , Heidenreich M , Mohanraju P , Fedorova I , Kneppers J , Degennaro EM , et al . Multiplex gene editing by CRISPR-Cpf1 using a single crRNA array . Nat Biotechnol . 2017 ; 35 ( 1 ): 31 – 4 .

Fonfara I , Richter H , Bratovič M , Le Rhun A , Charpentier E . The CRISPR-associated DNA-cleaving enzyme Cpf1 also processes precursor CRISPR RNA . Nature . 2016 ; 532 ( 7600 ): 517 – 21 .

Kim SK , Kim H , Ahn WC , Park KH , Woo EJ , Lee DH , et al . Efficient transcriptional gene repression by type V-A CRISPR-Cpf1 from eubacterium eligens . ACS Synth Biol . 2017 ; 6 ( 7 ): 1273 – 82 .

Zhang X , Wang J , Cheng Q , Zheng X , Zhao G , Wang J . Multiplex gene regulation by CRISPR-ddCpf1 . Cell Discov . 2017 ; 3 : 17018 .

Cong L , Ran FA , Cox D , Lin S , Barretto R , Habib N , et al . Multiplex genome engineering using CRISPR/Cas systems . Science . 2013 ; 339 ( 6121 ): 819 – 23 .

Hu JH , Miller SM , Geurts MH , Tang W , Chen L , Sun N , et al . Evolved Cas9 variants with broad PAM compatibility and high DNA specificity . Nature . 2018 ; 556 ( 7699 ): 57 – 63 .

Bi H , Fei Q , Li R , Liu B , Xia R , Char SN , et al . Disruption of miRNA sequences by TALENs and CRISPR/Cas9 induces varied lengths of miRNA production . Plant Biotechnol J . 2020 ; 18 ( 7 ): 1526 – 36 .

Paul B , Montoya G . CRISPR-Cas12a: functional overview and applications . Biomed J . 2020 ; 43 ( 1 ): 8 – 17 .

Abels ER , Maas SLN , Nieland L , Wei Z , Cheah PS , Tai E , et al . Glioblastoma-associated microglia reprogramming is mediated by functional transfer of extracellular miR-21 . Cell Rep . 2019 ; 28 ( 12 ): 3105 – 19.e7 .

Van Der Vos KE , Abels ER , Zhang X , Lai C , Carrizosa E , Oakley D , et al . Directly visualized glioblastoma-derived extracellular vesicles transfer RNA to microglia/macrophages in the brain . Neuro Oncol . 2016 ; 18 ( 1 ): 58 – 69 .

Nieland L , Van Solinge TS , Cheah PS , Morsett LM , El Khoury J , Rissman JI , et al . CRISPR-Cas knockout of miR21 reduces glioma growth . Mol Ther Oncolytics . 2022 ; 25 : 121 - 36 .

Gaudelli NM , Komor AC , Rees HA , Packer MS , Badran AH , Bryson DI , et al . Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage . Nature . 2017 ; 551 ( 7681 ): 464 – 71 .

Xie H , Tang L , He X , Liu X , Zhou C , Liu J , et al . SaCas9 requires 5'-NNGRRT-3' PAM for sufficient cleavage and possesses higher cleavage activity than SpCas9 or FnCpf1 in human cells . Biotechnol J . 2018 ; 13 ( 4 ): e1700561 .

Kleinstiver BP , Prew MS , Tsai SQ , Nguyen NT , Topkar VV , Zheng Z , et al . Broadening the targeting range of Staphylococcus aureus CRISPR-Cas9 by modifying PAM recognition . Nat Biotechnol . 2015 ; 33 ( 12 ): 1293 – 8 .

Pickar-Oliver A , Gersbach CA . The next generation of CRISPR-Cas technologies and applications . Nat Rev Mol Cell Biol . 2019 ; 20 ( 8 ): 490 – 507 .

Chatterjee P , Jakimo N , Jacobson JM . Minimal PAM specificity of a highly similar SpCas9 ortholog . Sci Adv . 2018 ; 4 ( 10 ): eaau0766 .

Yamada M , Watanabe Y , Gootenberg JS , Hirano H , Ran FA , Nakane T , et al . Crystal structure of the minimal Cas9 from Campylobacter jejuni reveals the molecular diversity in the CRISPR-Cas9 systems . Mol Cell . 2017 ; 65 ( 6 ): 1109 – 21.e3 .

Schindele P , Puchta H . Engineering CRISPR/LbCas12a for highly efficient, temperature-tolerant plant gene editing . Plant Biotechnol J . 2020 ; 18 ( 5 ): 1118 .

Kleinstiver BP , Sousa AA , Walton RT , Tak YE , Hsu JY , Clement K , et al . Engineered CRISPR-Cas12a variants with increased activities and improved targeting ranges for gene, epigenetic and base editing . Nat Biotechnol . 2019 ; 37 ( 3 ): 276 – 82 .

Morisaka H , Yoshimi K , Okuzaki Y , Gee P , Kunihiro Y , Sonpho E , et al . CRISPR-Cas3 induces broad and unidirectional genome editing in human cells . Nat Commun . 2019 ; 10 ( 1 ): 5302 .

Hsu JY , Grünewald J , Szalay R , Shih J , Anzalone AV , Lam KC , et al . Prime-Design software for rapid and simplified design of prime editing guide RNAs . Nat Commun . 2021 ; 12 ( 1 ): 1034 .

Kim HK , Lee S , Kim Y , Park J , Min S , Choi JW , et al . High-throughput analysis of the activities of xCas9, SpCas9-NG and SpCas9 at matched and mismatched target sequences in human cells . Nat Biomed Eng . 2020 ; 4 ( 1 ): 111 – 24 .

Kang SH , Lee WJ , An JH , Lee JH , Kim YH , Kim H , et al . Prediction-based highly sensitive CRISPR off-target validation using target-specific DNA enrichment . Nat Commun . 2020 ; 11 ( 1 ): 3596 .

Zhang XH , Tee LY , Wang XG , Huang QS , Yang SH . Off-target effects in CRISPR/Cas9-mediated genome engineering . Mol Ther Nucleic Acids . 2015 ; 4 : e264 .

Ren X , Yang Z , Xu J , Sun J , Mao D , Hu Y , et al . Enhanced specificity and efficiency of the CRISPR/Cas9 system with optimized sgRNA parameters in drosophila . Cell Rep . 2014 ; 9 ( 3 ): 1151 – 62 .

Matson AW , Hosny N , Swanson ZA , Hering BJ , Burlak C . Optimizing sgRNA length to improve target specificity and efficiency for the GGTA1 gene using the CRISPR/Cas9 gene editing system . PLoS One . 2019 ; 14 ( 12 ): e0226107 .

Gabriel R , Von Kalle C , Schmidt M . Mapping the precision of genome editing . Nat Biotechnol . 2015 ; 33 ( 2 ): 150 – 2 .

Clement K , Rees H , Canver MC , Gehrke JM , Farouni R , Hsu JY , et al . CRISPResso2 provides accurate and rapid genome editing sequence analysis . Nat Biotechnol . 2019 ; 37 ( 3 ): 224 – 6 .

Güell M , Yang L , Church GM . Genome editing assessment using CRISPR genome analyzer (CRISPR-GA) . Bioinformatics . 2014 ; 30 ( 20 ): 2968 – 70 .

Concordet J-P , Haeussler M . CRISPOR: intuitive guide selection for CRISPR/Cas9 genome editing experiments and screens . Nucleic Acids Res . 2018 ; 46 ( W1 ): W242 – 5 .

Liu H , Wei Z , Dominguez A , Li Y , Wang X , Qi LS . CRISPR-ERA: a comprehensive design tool for CRISPR-mediated gene editing, repression and activation . Bioinformatics . 2015 ; 31 ( 22 ): 3676 – 8 .

Montague TG , Cruz JM , Gagnon JA , Church GM , Valen E . CHOPCHOP: a CRISPR/Cas9 and TALEN web tool for genome editing . Nucleic Acids Res . 2014 ; 42 ( W1 ): W401 – 7 .

Park J , Bae S , Kim JS . Cas-Designer: a web-based tool for choice of CRISPR-Cas9 target sites . Bioinformatics . 2015 ; 31 ( 24 ): 4014 – 6 .

Meier JA , Zhang F , Sanjana NE . GUIDES: sgRNA design for loss-of-function screens . Nat Methods . 2017 ; 14 ( 9 ): 831 – 2 .

Moreno-Mateos MA , Vejnar CE , Beaudoin J-D , Fernandez JP , Mis EK , Khokha MK , et al . CRISPRscan: designing highly efficient sgRNAs for CRISPR-Cas9 targeting in vivo . Nat Methods . 2015 ; 12 ( 10 ): 982 – 8 .

Stemmer M , Thumberger T , Del Sol KM , Wittbrodt J , Mateo JL . CCTop: an intuitive, flexible and reliable CRISPR/Cas9 target prediction tool . PLoS One . 2015 ; 10 ( 4 ): e0124633 .

Abadi S , Yan WX , Amar D , Mayrose I . A machine learning approach for predicting CRISPR-Cas9 cleavage efficiencies and patterns underlying its mechanism of action . PLoS Comput Biol . 2017 ; 13 ( 10 ): e1005807 .

Chuai G , Ma H , Yan J , Chen M , Hong N , Xue D , et al . DeepCRISPR: optimized CRISPR guide RNA design by deep learning . Genome Biol . 2018 ; 19 ( 1 ): 80 .

Wong N , Liu W , Wang X . WU-CRISPR: characteristics of functional guide RNAs for the CRISPR/Cas9 system . Genome Biol . 2015 ; 16 ( 1 ): 218 .

Varshney GK , Zhang S , Pei W , Adomako-Ankomah A , Fohtung J , Schaffer K , et al . CRISPRz: a database of zebrafish validated sgRNAs . Nucleic Acids Res . 2016 ; 44 ( D1 ): D822 – 6 .

Zhao G , Li J , Tang Y . AsCRISPR: a web server for allele-specific sgRNA design in precision medicine . CRISPR J . 2020 ; 3 ( 6 ): 512 – 22 .

Chen W , Zhang G , Li J , Zhang X , Huang S , Xiang S , et al . CRISPRlnc: a manually curated database of validated sgRNAs for lncRNAs . Nucleic Acids Res . 2019 ; 47 ( D1 ): D63 – 8 .

Pattanayak V , Lin S , Guilinger JP , Ma E , Doudna JA , Liu DR . High-throughput profiling of off-target DNA cleavage reveals RNA-programmed Cas9 nuclease specificity . Nat Biotechnol . 2013 ; 31 ( 9 ): 839 – 43 .

Tyumentseva MA , Tyumentsev AI , Akimkin VG . Protocol for assessment of the efficiency of CRISPR/Cas RNP delivery to different types of target cells . PLoS One . 2021 ; 16 ( 11 ): e0259812 .

Basila M , Kelley ML , Smith AVB . Minimal 2'-O-methyl phosphorothioate linkage modification pattern of synthetic guide RNAs for increased stability and efficient CRISPR-Cas9 gene editing avoiding cellular toxicity . PLoS One . 2017 ; 12 ( 11 ): e0188593 .

Rahdar M , Mcmahon MA , Prakash TP , Swayze EE , Bennett CF , Cleveland DW . Synthetic CRISPR RNA-Cas9-guided genome editing in human cells . Proc Natl Acad Sci U S A . 2015 ; 112 ( 51 ): E7110 – 7 .

Wang X , Wang Y , Wu X , Wang J , Wang Y , Qiu Z , et al . Unbiased detection of off-target cleavage by CRISPR-Cas9 and TALENs using integrase-defective lentiviral vectors . Nat Biotechnol . 2015 ; 33 ( 2 ): 175 – 8 .

Thomson DW , Bracken CP , Goodall GJ . Experimental strategies for microRNA target identification . Nucleic Acids Res . 2011 ; 39 ( 16 ): 6845 – 53 .

Wu S , Huang S , Ding J , Zhao Y , Liang L , Liu T , et al . Multiple microRNAs modulate p21Cip1/Waf1 expression by directly targeting its 3' untranslated region . Oncogene . 2010 ; 29 ( 15 ): 2302 – 8 .

Kabadi AM , Ousterout DG , Hilton IB , Gersbach CA . Multiplex CRISPR/Cas9-based genome engineering from a single lentiviral vector . Nucleic Acids Res . 2014 ; 42 ( 19 ): e147 .

Kato Y , Tabata H , Sato K , Nakamura M , Saito I , Nakanishi T . Adenovirus vectors expressing eight multiplex guide RNAs of CRISPR/Cas9 efficiently disrupted diverse hepatitis B virus gene derived from heterogeneous patient . Int J Mol Sci . 2021 ; 22 ( 19 ): 10570 .

Asmamaw MM . Viral vectors for the in vivo delivery of CRISPR components: advances and challenges . Front Bioeng Biotechnol . 2022 ; 10 : 895713 .

Mout R , Ray M , Lee YW , Scaletti F , Rotello VM . In vivo delivery of CRISPR/Cas9 for therapeutic gene editing: progress and challenges . Bioconjug Chem . 2017 ; 28 ( 4 ): 880 – 4 .

Van Haasteren J , Li J , Scheideler OJ , Murthy N , Schaffer DV . The delivery challenge: fulfilling the promise of therapeutic genome editing . Nat Biotechnol . 2020 ; 38 ( 7 ): 845 – 55 .

Yip BH . Recent advances in CRISPR/Cas9 delivery strategies . Biomolecules . 2020 ; 10 ( 6 ): 839 .

Ricobaraza A , Gonzalez-Aparicio M , Mora-Jimenez L , Lumbreras S , Hernandez-Alcoceba R . High-capacity adenoviral vectors: expanding the scope of gene therapy . Int J Mol Sci . 2020 ; 21 ( 10 ): 3643 .

Ahi YS , Bangari DS , Mittal SK . Adenoviral vector immunity: its implications and circumvention strategies . Curr Gene Ther . 2011 ; 11 ( 4 ): 307 – 20 .

Luo Y , Xu X , An X , Sun X , Wang S , Zhu D . Targeted inhibition of the miR-199a/214 cluster by CRISPR interference augments the tumor tropism of human induced pluripotent stem cell-derived neural stem cells under hypoxic condition . Stem Cells Int . 2016 ; 2016 : 3598542 .

Hu YC . Baculovirus as a highly efficient expression vector in insect and mammalian cells . Acta Pharmacol Sin . 2005 ; 26 ( 4 ): 405 – 16 .

Drobna-Śledzińska M , Maćkowska-Maślak N , Jaksik R , Dąbek P , Witt M , Dawidowska M . CRISPRi for specific inhibition of miRNA clusters and miRNAs with high sequence homology . Sci Rep . 2022 ; 12 ( 1 ): 6297 .

Potter H , Heller R . Transfection by electroporation . Curr Protoc Mol Biol . 2018 ; 121 : 9.3.1-13 .

Lino CA , Harper JC , Carney JP , Timlin JA . Delivering CRISPR: a review of the challenges and approaches . Drug Deliv . 2018 ; 25 ( 1 ): 1234 – 57 .

Dasgupta I , Chatterjee A . Recent advances in miRNA delivery systems . Methods Protoc . 2021 ; 4 ( 1 ): 10 .

Chen F , Alphonse M , Liu Q . Strategies for nonviral nanoparticle-based delivery of CRISPR/Cas9 therapeutics . Wiley Interdiscip Rev Nanomed Nanobiotechnol . 2020 ; 12 ( 3 ): e1609 .

Ran F , Cong L , Yan WX , Scott DA , Gootenberg JS , Kriz AJ , et al . In vivo genome editing using Staphylococcus aureus Cas9 . Nature . 2015 ; 520 ( 7546 ): 186 – 91 .

Aquino-Jarquin G . CRISPR-Cas14 is now part of the artillery for gene editing and molecular diagnostic . Nanomedicine . 2019 ; 18 : 428 - 31 .

Chew WL , Tabebordbar M , Cheng JK , Mali P , Wu EY , Ng AH , et al . A multifunctional AAV-CRISPR-Cas9 and its host response . Nat Methods . 2016 ; 13 ( 10 ): 868 – 74 .

Alton EW , Armstrong DK , Ashby D , Bayfield KJ , Bilton D , Bloomfield EV , et al . Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial . Lancet Respir Med . 2015 ; 3 ( 9 ): 684 – 91 .

Behr M , Zhou J , Xu B , Zhang H . In vivo delivery of CRISPR-Cas9 therapeutics: progress and challenges . Acta Pharm Sin B . 2021 ; 11 ( 8 ): 2150 – 71 .

Lin Y , Wu J , Gu W , Huang Y , Tong Z , Huang L , et al . Exosome-liposome hybrid nanoparticles deliver CRISPR/Cas9 system in MSCs . Adv Sci (Weinh) . 2018 ; 5 ( 4 ): 1700611 .

Duan L , Ouyang K , Xu X , Xu L , Wen C , Zhou X , et al . Nanoparticle delivery of CRISPR/Cas9 for genome editing . Front Genet . 2021 ; 12 : 673286 .

Steinmetz NF , Lim S , Sainsbury F . Protein cages and virus-like particles: from fundamental insight to biomimetic therapeutics . Biomater Sci . 2020 ; 8 ( 10 ): 2771 – 7 .